Insider Buying: KindlyMD (NASDAQ:NAKA) CEO Acquires 104,833 Shares of Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey purchased 104,833 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were acquired at an average cost of $4.84 per share, for a total transaction of $507,391.72. Following the transaction, the chief executive officer owned 3,120,361 shares of the company’s stock, valued at $15,102,547.24. This trade represents a 3.48% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

KindlyMD Price Performance

NASDAQ NAKA opened at $5.40 on Thursday. The firm has a market cap of $93.96 million, a P/E ratio of -0.13 and a beta of 17.12. The stock’s 50-day moving average is $8.31 and its 200-day moving average is $13.24. KindlyMD, Inc. has a one year low of $4.50 and a one year high of $1,120.00.

KindlyMD (NASDAQ:NAKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($15.20) EPS for the quarter. The business had revenue of $2.68 million for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%. Equities analysts anticipate that KindlyMD, Inc. will post -16.8 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on NAKA shares. Weiss Ratings raised KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Wall Street Zen raised KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. TD Cowen started coverage on KindlyMD in a research report on Friday, April 10th. They issued a “buy” rating and a $40.00 target price on the stock. B. Riley Financial dropped their target price on KindlyMD from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, February 23rd. Finally, Maxim Group dropped their target price on KindlyMD from $60.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, KindlyMD has an average rating of “Hold” and an average target price of $30.00.

Institutional Investors Weigh In On KindlyMD

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sagespring Wealth Partners LLC acquired a new stake in KindlyMD in the 4th quarter valued at approximately $28,000. SG Americas Securities LLC acquired a new stake in KindlyMD in the 4th quarter valued at approximately $61,000. Virtu Financial LLC acquired a new stake in KindlyMD in the 4th quarter valued at approximately $151,000. J. Derek Lewis & Associates Inc. acquired a new stake in KindlyMD in the 4th quarter valued at approximately $167,000. Finally, Truist Financial Corp bought a new position in KindlyMD in the fourth quarter valued at approximately $176,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.